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Breast cancerTartrate-resistant acid phosphatase, although encoded by a single gene, exists as two isoforms in human
serum, TRAP 5a and 5b, differing in post-translational modiﬁcations such as proteolytic processing and
kinetic properties including pH optimum and speciﬁc activity. The biogenetic relationship between the TRAP
isoforms was assessed in a stably transfected breast cancer epithelial MDA-MB-231 cell subline
overexpressing 5a- and 5b-like TRAP isoforms intracellularly, with only the monomeric 5a-like isoform
being secreted. As judged by immunolocalization and comparative N-glycan proﬁling by Con A lectin
chromatography and glycanase analysis, the majority of the intracellular monomeric TRAP was destined for
secretion, while a minor portion provided the putative precursor for the intracellular 5b-like isoform.
Brefeldin A blocked secretion of 5a-like TRAP isoform as well as appearance of its putative intracellular
precursor, and augmented the intracellular level of proteolytically processed 5b-like isoform, indicating a
common early biosynthetic precursor for TRAP isoforms 5a and 5b. The cysteine proteinase inhibitor E64
partially blocked formation of the 5b-like isoform while augmenting the level of its putative monomeric
precursor, but did not alter the levels of secreted TRAP or its intracellular precursor, suggesting that distinct
precursors for secreted TRAP 5a and intracellular 5b-like isoform are segregated in the ER or Golgi prior to
proteolytic processing. In conclusion, these data provide evidence that distinct monomeric TRAP populations
are diverted early in the secretory pathway either giving rise to a secreted, monomeric 5a-like TRAP isoform
or to an intracellular, proteolytically processed 5b-like TRAP isoform.atase; FPLC, fast protein liquid
n A; pNPP, p-nitrophenylpho-
-methylcoumarin
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Tartrate-resistant acid phosphatase (TRAP), also known as type 5
acid phosphatase (Acp 5, EC 3.1.3.2), purple acid phosphatase or
uteroferrin, is an acidic metallohydrolase with a binuclear iron metal
center in its active site [1,2]. TRAP contains two potential N-
glycosylation sites and is synthesized as a monomeric N-glycosylated
polypeptide of 35–37 kDa [3], but is commonly isolated from tissues
as a two-subunit form, consisting of a 21–23 kDa N-terminal domain
disulﬁde-linked to a 16–17 kDa C-terminal domain [4–6]. The active
two-subunit form can be generated in vitro frommonomeric TRAP by
limited proteolysis of a repressive loop domain by cathepsins K, L and
B [5–7]. Analysis of cathepsin K−/−mice indicated that cathepsin K isinvolved in proteolytic processing in vivo as well as contributes to
sorting of TRAP in a sub-population of metaphyseal osteoclasts [8].
In mammals, TRAP is abundantly expressed by cells of monocyte–
macrophage lineage as well as in neurons and epithelial lining cells of
colon, lung and kidney [9–13]. Notably, several human breast cancer
cell lines and tissues express TRAP where the intensity of histochem-
ical activity correlates with the degree of tumorigenicity [14,15].
Human serum contains TRAP isoforms 5a and 5b, where monomeric
5a constitute themajor isoform representing 80–90% of the total TRAP
protein although contributing less to total serum TRAP activity
because of lower speciﬁc enzyme activity compared to the proteolyt-
ically processed 5b isoform [16,17].
The 5a isoformmay act as a growth factor to promote proliferation
and differentiation of osteoblastic cells [18] and adipocytes [19]. The
5a form is selectively increased in serum from rheumatoid arthritis
patients in the absence of bone involvement [17] and has been
advocated as a marker for certain inﬂammatory conditions. The
proteolytically processed 5b-like isoform can act as a protein
phosphatase [20,21] and can form reactive oxygen species potentially
important for phagosomal/endosomal degradation [22]. TRAP 5b
activity in serum correlates with osteoclast numbers [23–25] and is
altered in disorders of bone resorption [26–31]. It also serves as a
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Moreover, phosphatase activity of TRAP has recently been assigned
roles in removal of mannose 6-phosphate recognition marker [33],
and regulation of osteoclast migration on post-translationally mod-
iﬁed, i.e. phosphorylated, osteopontin [34].
TRAP is encoded by a single gene and the monomeric isoform
could potentially act as a biosynthetic precursor to the proteolytically
processed/cleaved isoform. Since monomeric 5a and cleaved 5b
isoforms appear to exert distinct functions, and correlate indepen-
dently with different human diseases, the availability of cell systems
to analyse the post-translational mechanisms important for the
distribution and functional activities of these isoforms is needed. To
address these questions, we generated a stable MDA-MB-231 breast
cancer epithelial cell line overexpressing 5a- and 5b-like TRAP
isoforms.
2. Materials and methods
2.1. Materials
The breast cancer cell line MDA-MB-231 was purchased from the
American Type Culture Collection (Rockville, MD, USA). Alkaline
phosphatase-conjugated goat anti-rabbit IgG was purchased from
Sigma (St. Louis, MO, USA). The polyclonal cathepsin K antiserumwas
produced in rabbits using a synthetic peptide derived from the mouse
cathepsin K sequence according to [35]. The antiserum against total
TRAP, recognizing both the monomeric and the cleaved variants of
TRAP, was produced in rabbits with recombinant monomeric rat TRAP
as described in [4]. Antiserum towards the exposed loop domain in
TRAP (which is excised by cathepsin K), selectively recognizing the
monomeric, uncleaved TRAP 5a, was generated in rabbits using a
peptide derived from the mouse TRAP sequence (146DDFASQ-
QPKMPRDLGVA162) as the immunogen [12]. ER-membrane marker
mouse monoclonal antibody anti-calnexin and Golgi marker mouse
monoclonal anti-giantin were purchased from Abcam (Cambridge,
UK). Alexa-conjugated secondary antibodies and ELF97 Endogenous
Phosphatase Detection Kit was purchased from Molecular Probes
(Invitrogen Co., Eugene, OR, USA). The cysteine proteinase inhibitor
E64 (L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane) was
purchased from Roche (Mannheim, Germany). Cathepsin B inhibitor
CA-074-Me ([L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L-iso-
leucyl-L-proline Methyl Ester) was purchased from Calbiochem (La
Jolla, CA). Brefeldin A was purchased from Sigma (St. Louis, MO, USA).
PNGase F and Endo H were purchased from New England Biolabs
(Hertfordshire, UK). HiTrapTM Heparin HP and HiTrapTM Con A 4B
columns were purchased from GE Healthcare (Uppsala, Sweden).
2.2. Stable transfection of MDA-MB-231 cells
MDA-MB-231 cells were stably transfected with the eukaryotic
expression vector pcI-neo (Promega Corp. , Madison, WI) containing
the full-size 1.4 kb rat TRAP insert [3] to generate stable MDA-MB-231
transfectants overexpressing TRAP. Lipid-mediated transfection was
performed with Lipofectamine2000 according to the manufacturer's
protocol (Invitrogen, San Diego, CA). Brieﬂy, 3×105 cells were seeded
per well in a 6-well culture plate (Costar, Cambridge, MA, USA) 48h
before the transfection. Two µg plasmid DNAwas complexedwith 7 µl
Lipofectamine 2000 reagent in opti-MEM medium (Invitrogen) and
incubated with the cells at 70% conﬂuency for 5 h at 37 °C in culture
medium (RPMI-1640 culture medium (SIGMA) containing 10% heat-
inactivated fetal bovine serum (GIBCO, USA) and 50 mg/l gentamicin).
Following transfection, cells were cultured in fresh medium over-
night. The day after transfection, near conﬂuent cells were split at a
ratio of 1:6 and selection was started 48 h after transfection with
400 µg/mL geneticin. Selection medium was changed every second
day, and geneticin-resistant cell clones were isolated and tested forexpression of TRAP using the Leukocyte acid phosphatase staining kit
(Sigma) in the presence of 10 mM tartrate. The clone MDA-C11 that
showed the highest expression of TRAP activity in medium was
chosen for further analysis. TRAP expression in the clone at the mRNA
level was conﬁrmed using previously published primers [12].
2.3. Puriﬁcation of recombinant TRAP from MDA-C11 cells
Conditioned media from parental MDA-MB-231 cells or clone
MDA-C11 was harvested and stored at −20 °C until analysis. Cells
were trypsinized, scraped and centrifuged at 500 ×g for 5 min. 100 µl
lysis buffer (0.15 M KCl, 0.1% Triton X-100)/1×106 cells were added
onto pelleted cells in the presence of proteinase inhibitor cocktail
Complete (Roche Diagnostic GmbH, Mannheim, Germany). After
homogenisation by a Polytron rotor-stator homogeniser and centri-
fugation at 12000 ×g for 15 min at 4 °C, supernatants and harvested
medium were used for Heparin FPLC, activity measurements and
Western blot analysis.
2.4. Heparin FPLC Separation of TRAP
Separation of monomeric and cleaved forms of TRAP from lysates
or media was performed according to [36] using an ÄKTApuriﬁer™ 10
FPLC system (GE Healthcare, Sweden) at 4 °C with a Heparin column
(ﬂow rate 2 ml/min) equilibrated with 20 mM Tris–HCl, pH 7.2, 0.1 M
NaCl, 0.005% Triton X-100 (w/v). Protein was eluted by a linear
gradient of NaCl from 0.1 to 0.9 M NaCl in 20 mM Tris–HCl, pH 7.2,
0.005% Triton X-100 (w/v) and collected in 2 ml-fractions.
2.5. Con A lectin chromatography
Separation of TRAP isoforms according to their carbohydrate
content was performed using an ÄKTApuriﬁer™ 10 FPLC system (GE
Healthcare, Sweden) at 30–35 °C with a Con A (Concanavalin A)
column (ﬂow rate 0.5 ml/min) equilibrated with 20 mM Tris–HCl,
0.5 M NaCl, 1 mM MnCl2, 1 mM CaCl2, pH 7.4, 0.005% Triton X-100
(w/v). Protein was eluted by a linear gradient of 0 to 1 Mmethyl-α-D-
mannopyranoside in 20 mM Tris–HCl, 0.5 M NaCl, pH 7.4, 0.005%
Triton X-100 (w/v) and collected in 0.5 ml-fractions.
2.6. Protein quantiﬁcation and acid phosphatase activity assay
Protein concentrations were determined using the BCA method
(Pierce, Rockford, Il, U.S.A.). TRAP activity was measured using
p-nitrophenyl-phosphate (pNPP) as the substrate as described previ-
ously [12]. Parallel incubations also contained 100 µM molybdate and
molybdate-sensitive activity was regarded as a measure of tartrate-
resistant acid phosphatase activity.
2.7. Kinetic analysis of TRAP
For TRAP kinetic analysis, pNPP was used as the substrate as
described in [37,38]. In short, all reactions were performed in
duplicate using 0.2–50 mM substrate (ﬁnal concentrations) at 37 °C.
KM values was calculated by non-linear regression analysis and
plotted as Lineweaver–Burk plots using the Origin software (Microcal
Software, Inc. Northhampton, MA, USA). ). The pH optima of C11-
TRAP were measured using 0.1 M NaAc buffer, pH 4.5–6.5. All
measurements were repeated at least twice and results were
averaged from different enzyme preparations.
2.8. Proteolytic digestion of TRAP
The cleavage of TRAP with recombinant human mature cathepsin K
(12.6 U/mg protein) [39] was performed with ﬁnal concentrations of
0.3 mU/µl TRAP, 12 ng/µl cathepsin K for pools L1a and M1; 0.6 mU/µl
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50 mM sodium acetate, pH 5.5 and 1 mM EDTA in a ﬁnal volume of
100 µl and incubated at 37 °C for 2 h. The reaction was stopped by the
addition of the proteinase inhibitor cocktail Complete (Boehringer
Mannheim, Germany).
2.9. Western blotting
Heparin FPLC puriﬁed TRAP was subjected to 12% SDS-PAGE under
reducing conditions. Proteins were electroblotted to immuno-PVDF
membranes (Bio-Rad) and blocked for 1 h at room temperature in 1%
Tween 20 in TBS (20 mM Tris, pH 7.5, 500 mM NaCl). The membranes
were then incubated with anti-total TRAP (diluted 1:1000) for 1 h at
room temperature, washed three times for 10 min each in TBST (TBS+
0.05% Tween 20) before incubation with secondary antibody (alkaline
phosphatase-conjugated goat anti-rabbit IgG, diluted 1:500), washed,
and developed. Development was performed with NBT/BCIP (Roche
Diagnostics GmbH, Mannheim, Germany).
2.10. Immunoﬂuorescence
MDA-C11 cells stably expressing TRAP were seeded in a Lab-Tek
chamber slide (Nalge Nunc International Corp, Naperville, IL, USA)
and ﬁxed either by 4% formaldehyde (for calnexin and monomeric
TRAP colocalization) in PBS for 15 min followed by permeabilization
using 1% Triton X-100 in TBST (20 mMTris–HCl, pH 7.4, 500 mMNaCl,
0.1% Tween 20) for 20 min at room temperature (RT) or by methanol
(for giantin and monomeric TRAP colocalization) at−20 °C for 5 min
and then blocked in 0.1% BSA in TBST for 20 min. For ER and Golgi
staining, cells were incubated with 1:200 dilution of mouse
monoclonal antibodies anti-calnexin or anti-giantin, respectively for
1 h at RT. For TRAP staining, cells were incubated with rabbit
polyclonal anti-monomeric TRAP for 1 h at RT. After three washings
with TBST, cells were incubated, depending on primary antibody,
either with anti-rabbit-IgG (1:200) or anti-mouse-IgG (1:200)
conjugated to Alexa-488 or Alexa-568 for 30 min at RT and then
washed as above. After washing, slides were mounted with coverslips
using Fluorescent Mounting Media (DAKO, Glostrup, Denmark).
Images were taken with LEICA DM IRBE microscope and processed
with Openlab 2.0.3 image analysis software (Improvision, Lexington,
USA).
2.11. Fluorescence-based staining for TRAP activity with ELF97
Formalin-ﬁxed cells were rinsed in PBS for 10 min and then
incubated with ELF97 substrate diluted 1:20 in dilution buffer
(100 mM acetate buffer, pH 5.2; 1 mM sodium nitrite; 7.4 mM
tartrate) for 5 min as described in [40]. After the incubation, reaction
was stopped by addition of wash buffer (PBS; 25 mM EDTA, pH 8.0;
10 mM Na-tartrate; 100 µM molybdate) followed by washing three
times in the same buffer for 5 min. For double stainings, the washings
were followed by permeabilization and subsequent antibody staining
as described above in 2.10.
2.12. Endoglycosidase digestion of TRAP
For digestion with PNGase F, Heparin FPLC fractions containing
5 mU monomeric TRAP (L1a, L1b and M1 forms) or 20 mU
proteolytically processed TRAP (L2 and L3 forms) were boiled for
10 min in 0.5% SDS and 0.04 M dithiothreitol. Then NP-40 was added
to a ﬁnal concentration of 1% together with 500 mU of PNGase F in
0.05 M sodium phosphate buffer, pH 7.5, and incubated at 37 °C for
2 h. For digestion with Endoglycosidase H, samples were boiled as
described for PNGase F, followed by addition of 500 mU recombinant
Endoglycosidase H in 0.05 M sodium citrate buffer, pH 5.5, and
incubated for 2 h at 37 °C.2.13. Treatment with Brefeldin A, E64 or CA-074-Me
MDA-C11 cells were cultured at 5×105 cells/dish in 100-mm
dishes from Sarstedt (Numbrecht, Germany). The cysteine proteinase
inhibitor E64 (30 μM ﬁnal concentration) or CA-074-Me (1 μM ﬁnal
concentration) was included in the media and fresh inhibitor was
added every day for 3 days. After 3 days of culture, both cells and
conditioned media were harvested as described previously. A small
amount of cell lysate from whose lysis buffer proteinase inhibitor was
excluded was used to conﬁrm the inhibition of cysteine proteinase
activity (data not shown).
Brefeldin A was added to near conﬂuent cells in 100 mm dishes to
a ﬁnal concentration of 50 µM. After 6 h of incubation, lysate and
media were collected as described previously.
2.14. Statistical analysis
Statistical analyses were performed with Student's t-test. A
probability value (P) of less than 0.05 was considered signiﬁcant.
3. Results
3.1. Generation of stable MDA-MB-231 cell lines expressing rat
recombinant TRAP
The full-length rat TRAP cDNA inserted into the pcI-neo vector was
transfected into MDA-MB-231 cells using Lipofectamine at 30–40%
efﬁciency. After G418 selection for 2 weeks, ﬁve colonies were picked
for subsequent subcloning. Out of these ﬁve colonies, clone MDA-C11
expressed the highest level of TRAP enzyme activity, both intracel-
lularly and as a secreted product, and therefore chosen for further
characterization. In contrast to MDA-MB-231 parental cells, the MDA-
C11 clone displayed strong histochemical TRAP staining (Fig. 1). TRAP
activity in lysates was 35-fold higher for MDA-C11 cells compared to
the parental cells. Stably transfected cells accumulated 250-fold
higher TRAP activity in the medium during a 24-hour period
compared to parental cells (Table 1). Interestingly, TRAP-overexpres-
sing cells displayed a more compact and rounded morphology
compared to a more elongated shape of parental cells (Fig. 1). The
effect of TRAP overexpression on cell morphology was evaluated by
determination of cell length/cell width ratio, where parental cells
exhibited a signiﬁcantly higher ratio (3.4±3.0; n=28) compared to
TRAP-overexpressing MDA-C11 cells (2.2±1.1; n=27); p=0.004.
This morphological phenotype is consistent with previous observa-
tions on TRAP-overexpressing RAW264.7 cells [41].
3.2. Biochemical characterization of secreted and intracellular TRAP
forms expressed by MDA-C11 cells
Heparin ion-exchange FPLC has proven useful to separate
monomeric and different proteolytically processed forms of TRAP
[7,8,36–38]. We have previously shown that TRAP from rat andmouse
bone andmouse TRAP expressed by osteoclastic cells derived from the
myeloid RAW264.7 cell line exhibited an elution proﬁle with three
separable peaks where the ﬁrst eluted minor peak, denoted as peak 1,
represent the monomeric form and major peaks 2 and 3 represent
differentially cleaved TRAP isoforms [7,8].
Similar to rat andmouse osteoclastic TRAP [7,8], intracellular TRAP
expressed by MDA-C11 cells eluted in two late peaks at around 0.7 M
and 0.85 M NaCl, denoted as L2 and L3, respectively, with a
predominance of the L3 (Fig. 2a). At variance to rat and mouse
osteoclasts [7,8], MDA-C11 cells expressed an additional prominent
TRAP peak eluting around 0.5 M NaCl (L1a), as well as a minor
shoulder eluting at 0.6 M NaCl (L1b). Western blot analysis showed
that the L1a and L1b fractions contain differently sized monomeric
forms of TRAP (Fig. 2b). The monomeric constituent of the L1b
Fig. 1. Cytochemical staining for TRAP activity in parental MDA-MB-231 cells and the
TRAP-transfected MDA-C11 cells (20× magniﬁcation).
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of the L1a fraction, which was heterogenous containing one stronger
lower band and a weaker upper band. Both proteolytic fragments of
L2 migrated slower than those of L3, consistent with previous data [7]
suggesting that L2 form represents an intermediate product in the
ﬁnal processing to L3.
TRAP secreted by MDA-C11 cells eluted as a single peak, denoted
as M1, at around 0.5 M NaCl, coincident with the elution proﬁle of L1a
(Fig. 2a). Interestingly, MDA-C11-secreted TRAP did not produce an
L1b-like shoulder at 0.6 M NaCl upon heparin FPLC fractionation.
Western blot analysis of the M1 fraction displayed several monomeric
TRAP species with slightly higher or similar molecular weights
compared to the L1a isoforms. The observation that secreted M1
and intracellular L1a isoforms eluted at the same salt concentration
and that both contains monomeric forms with molecular weights
slightly higher than L1b form prompted us to consider the possibility
that L1a mostly consists of TRAP destined for secretion, i.e. M1 in our
system, whereas the monomeric L1b form might function as the
precursor for the intracellular cleaved forms L2 and L3. To this end, we
compared the N-glycosylation proﬁles of partially puriﬁed TRAP forms
by digestion with PNGase F or Endoglycosidase H. PNGase F cleaves
between the innermost GlcNAc and asparagine residues of high-
mannose, hybrid and complex oligosaccharides from N-linkedTable 1
Comparison of TRAP activity between TRAP-overexpressing MDA-C11 and parental
MDA-MB-231 cells.
n TRAP activity in lysates
(mU/µg protein)
n TRAP activity in media
(mU/106 cells/day)
MDA-MB-231 3 0.009 (0.009) 3 0.19 (0.19)
MDA-C11 3 0.314 (0.043) 3 54.84 (27.22)
Numbers in parentheses represent standard deviation values.glycoproteins, whereas Endo H cleaves N-linked high-mannose and
hybrid-type, but not complex-type oligosaccharides [42]. Thus,
comparison of Endo H sensitivity between different forms might be
used to indicate potential biosynthetic relationships. Western blot
analysis showed that all monomeric forms (L1a, L1b and M1) and the
larger N-terminal fragment of the cleaved forms (L2 and L3) were
completely shifted upon PNGase F treatment (Fig. 2c; only shown for
M1). Digestion of monomeric forms with EndoH revealed that both
L1a and M1 fractions were partially sensitive to EndoH whereas the
same treatment caused a complete shift of the monomeric L1b form
(Fig. 2c). Similar to the L1b, also the L2 and L3 forms showed complete
sensitivity to Endo H (Fig. 2d). To further clarify the possible
biogenetic relationship between L1a and M1 as well as L1b and
cleaved isoforms, we applied samples of the different TRAP isoforms
to Con A-Sepharose columns. Con A (Concanavalin A) is a lectin that
binds molecules containing α-D-mannopyranosyl, α-D-glucopyrano-
syl and sterically related residues and is commonly used to
differentially isolate glycoisoforms. We found that both M1 and L1a
gave major peaks eluting at 0.4–0.45 M methyl-α-D-mannopyrano-
side. In addition to this major peak, a minor peak eluting at 50 mM
eluent concentration was observedwith L1a (Fig. 2e). L1b and cleaved
form L2, on the other hand, eluted at a lower concentration of 0.3–
0.35 M (Fig. 2f). Overall, the N-glycosylation proﬁles, judged by
endoglycosidase analysis and Con A chromatography, of different
TRAP forms is consistent with the notion that the secreted TRAP (M1)
is derived from L1a, whereas the intracellularly located cleaved forms
L2 and L3 are generated by the proteolytic processing of the
monomeric L1b form.
3.3. Blockage of ER–Golgi transport by Brefeldin A indicates a common
precursor pool for intracellular and secreted TRAP forms
Brefeldin A (BfA) is a fungal antibiotic which interferes with
protein transport from the endoplasmic reticulum (ER) to the Golgi
apparatus, leading to protein accumulation in the ER and inhibition of
secretion [43]. We treated MDA-C11 cells with 50 µM Brefeldin A for
6 h in culture to study its effect on secretion and intracellular
retention of TRAP. BfA caused up to 80% decrease in the amount of
secreted TRAP, whereas intracellular TRAP activity remained un-
changed (Fig. 3a). Heparin chromatography conﬁrmed that the BfA
treatment affected the level of secreted TRAP activity due to the
monomeric form (Fig. 3b). FPLC analysis of intracellular TRAP forms
showed that L1b and L2 activity remained unchanged, whereas L1a
activity was decreased concomitant with an increase of the ﬁnal
cleavage product L3 (Fig. 3c). Thus, the disappearance of the L1a
activity parallels increased L3 activity, explaining the unchanged TRAP
activity of cell lysates from BfA-treated compared to untreated cells.
That the abundance of TRAP isoforms of both the L1a andM1 fractions
is extensively attenuated in the presence of BfA further indicates that
the L1a isoforms are transported through the ER–Golgi–plasma
membrane axis. Moreover, the absence of an attenuating effect of
BfA on L1b, L2 and L3 suggests that these isoforms are transported
through and/or localized in an intracellular pathway other than ER–
Golgi–plasma membrane axis.
Western blot analysis of L1a and M1 fractions of MDA-C11 cells
following Brefeldin A treatment (Fig. 3d) showed that a monomeric
TRAP isoform with higher molecular weight accumulated inside the
cells upon treatment whereas the isoform with lower molecular
weight was secreted to the media, suggesting that the larger
monomeric isoform accumulating inside the cells represents the ER-
form (endoplasmic reticulum), whereas the onewith lowermolecular
weight is generated in intracellular compartments subsequent to the
site of Brefeldin A action.
Immunoﬂuorescence studies showed that monomeric TRAP was
localized to endoplasmic reticulum (ER) (Fig. 4a–c) and Golgi
(Fig. 4d–f), but not vacuolar compartments. However, TRAP activity,
Fig. 2. (a) Elution pattern of TRAP activity from FPLC Heparin chromatography of lysate from and media conditioned by MDA-C11 cells. Bound TRAP was eluted with a 0.1–0.9 M
NaCl gradient in 20 mM Tris–HCl, pH 7.2 with 0.005% Triton X-100. Fractions were assayed for molybdate-sensitive TRAP activity using pNPP as substrate and the group of
fractions that constitute distinct peaks were denoted as L1a, L1b, L2 and L3 for lysate and M1 for media. Horizontal bars under the peaks indicate the fractions pooled for further
analysis. (b) Western blot analysis of eluted TRAP peaks of lysate and media from MDA-C11 cells. Pooled and concentrated fractions of the different TRAP activity peaks
corresponding to 10 mU for L1a, L1b andM1 pools and 30 mU for L2 and L3 pools were subjected to 12% SDS-PAGE under reducing conditions, blotted onto a PVDFmembrane, and
probed with anti-total TRAP antibody. (c, d) N-glycosylation pattern of (c) monomeric and (d) proteolytically processed TRAP forms expressed by MDA-C11 cells. Following
incubation with (+) or without (−) Endoglycosidase H (Endo H) or PNGase F, proteins were analysed as described above. (e, f) Elution pattern of TRAP activity from Con A
(Concanavalin A) chromatography of M1 and L1a (e) and L1b and L2 (f) isoforms of TRAP. Bound TRAP was eluted at 30–35 °C with a 0–1 M methyl-α-D-mannopyranoside
gradient in 20 mM Tris–HCl, 0.5 M NaCl, pH 7.4, 0.005% Triton X-100 (w/v). Fractions were assayed for molybdate-sensitive TRAP activity using pNPP as substrate.
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Fig. 3. Effect of Brefeldin A (BfA) treatment on TRAP distribution inMDA-C11 cells. (a)TRAP activity in cell lysates and conditioned medium inMDA-C11 cells before and after treatment
with BfA. Data are presented as mean of three experiments±SD. *Pb0.05 vs. untreated. (b, c) Elution pattern from FPLC Heparin chromatography of (b) TRAP secreted byMDA-C11 cells
and (c) cellular TRAP following treatmentwith BfA. Equal volumes ofmedia (b) or lysates containing equal amounts of protein (c)were loadedonto the column for eachgroup. (d)Western
blot analysis of TRAP peaks L1a andM1 fromMDA-C11 cells treatedwith (+) orwithout (−) BfA. 10 mUof pooled and concentrated fractions of the TRAP activity peakswere subjected to
12% SDS-PAGE under reducing conditions, blotted onto a PVDF membrane, and probed with anti-total TRAP antibody.
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hydrolysis of ﬂuorescent ELF97 phosphatase substrate, was detected
in vacuolar compartments (Fig. 4g). Moreover, no obvious colocaliza-
tion was observed between the ER marker calnexin and active/
cleaved form of TRAP (Fig. 4g–i).
3.4. Cysteine proteinases are involved in proteolytic processing of TRAP
in MDA-C11 cells
It has previously been shown that cysteine proteinases such as
cathepsin K, L and B can process and activate monomeric TRAP in vitro
[6,7,44] , and that TRAP processing is altered in mice genetically
deﬁcient in cathepsin K [8]. Previously, these three proteases have
also been shown to be expressed by MDA-MB-231 cells [45,46]. Since
the FPLC Heparin proﬁle of intracellular TRAP expressed by MDA-C11
cells displayed a proteolytic fragmentation pattern (L2 and L3 in
Fig. 2a) indicative of a cysteine proteinase-like cleavage [8], the cells
were treated with the cysteine proteinase inhibitor E64 for 3 days in
culture to explore whether cysteine proteinases are involved in the
proteolytic processing of TRAP in MDA-C11 cells. E64 treatment did
not cause a signiﬁcant change in TRAP activity neither in media nor in
cell lysates (Fig. 5a). Next, the cell extracts and conditioned media
from MDA-C11 cells were chromatographed on Heparin columns to
assess the possible effect of E64 on proteolytic processing of TRAP. The
inhibitor did not have any effect on the activity levels of L1a and M1
(Fig. 5b and c), whereas L1b and L2 activity was increased at the
expense of the ﬁnal cleavage product L3. The identity of the peaks wasconﬁrmed by Western blot (Fig. 5d). This response to E64 is highly
reminiscent of what previously was shown for RAW264.7 cells
differentiated to osteoclast-like cells by RANKL [8]. Treatment of the
cells with cathepsin B/L inhibitor CA-074-Me, on the other hand, had
only a slight effect on proteolytic processing of TRAP (Fig. 5e). Overall,
our data demonstrate that cysteine proteinases are involved in a ﬁnal
step of the proteolytic processing of intracellular TRAP in MDA-C11
cells, where the monomeric L1b form provides the putative precursor
to the cleaved fragments L2 and L3. The absence of an effect of E64 on
secreted TRAP (M1) and its putative intracellular precursor (L1a
fraction) underscores the existence of distinct precursor pools for
secreted and intracellular TRAP.
3.5. Kinetic characterization of monomeric and cleaved TRAP forms
expressed by MDA-C11 cells
Among the proteases known to be able to cleave and activate
TRAP, cathepsin K is the protease that exerts most extensive
processing on the repressive loop domain of TRAP and the only
enzyme that activates TRAP to physiological levels of the cleaved TRAP
isolated from bone [7]. Therefore, cathepsin K digestion can be
employed to infer about the activation and proteolytic status of
different TRAP isoforms. Enzyme kinetic analysis of partially puriﬁed
monomeric and cleaved forms of TRAP expressed by MDA-C11 cells
was performed by deriving the kinetic constant KM from Lineweaver–
Burk plots using substrate concentrations from 0.2 to 50 mM at 37 °C
and pH 5.8 (Table 2). Digestion of medium M1 and intracellular L1a
Fig. 4. Intracellular localization of monomeric and cleaved isoforms of TRAP in MDA-C11 cells. Double immunoﬂuorescence staining using a polyclonal anti-monomeric TRAP
antibody (mTRAP) (a, d) and either monoclonal anti-calnexin antibody as ERmarker (b) or anti-giantin antibody as Golgi marker (e) demonstrate localization of monomeric TRAP in
ER (c) and Golgi (f). Colocalization analysis of TRAP activity by ﬂuorescent substrate ELF97 (g) and anti-calnexin (h) shows predominant localization of TRAP activity in cytoplasmic
vesicles and minimal localization in the ER (i). Original magniﬁcation, 40×.
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were completely converted to processed forms (data not shown)
resulted in 6.2- and 4.7-fold increases in TRAP activity, respectively
(Table 2). Digesting L2 and L3 forms with cathepsin K did not further
increase their TRAP activity, implying a cathepsin K-like cleavage of in
vivo proteolytic processed forms of TRAP in this cell line.
We have previously shown that monomeric TRAP from different
sources exhibits a decreased afﬁnity constant upon cleavage by cathepsin
K [7,12,38]. Interestingly, cathepsin K digestion had no effect onKMvalues
of the monomeric forms (L1a and M1) expressed by MDA-C11 cells
(Table 2). However, lower KM values were associatedwith proteolytically
processed endogenous forms L2 and L3 compared to cathepsinK-digested
monomeric forms of L1a and M1, which could be attributable to yet
unknown factors independent of proteolytic processing.
TRAP usually exhibits a pH optimum for the hydrolysis of
phosphomonoesters ranging from 4.5 to 6.5. Proteolytic processing
of the monomeric form, whose activity peaks at pH 5, with cysteine
proteinases such as cathepsin K or L causes a shift in optimal pH to
more basic values, i.e. around pH 6 [5,7,12,16,38]. Monomeric forms of
M1 and L1a expressed in MDA-C11 cells exhibited a broad pH
optimum at around pH 5.5, whereas the pH optimum of cleaved L3
form was shifted to slightly more basic values, i.e. 5.75 (Table 2).
Cleavage of the monomeric forms of M1 and L1a with cathepsin K
caused a slight shift in the optimal pH to 5.75, whereas the pH
optimum of the cleaved L3 form was not further shifted following
digestion with cathepsin K (Table 2).4. Discussion
Human TRAP exists in tissues and ﬂuids as two isoforms denoted
TRAP 5a and 5b. TRAP isoform 5a comprises a monomeric polypeptide
whereas isoform 5b consists of a proteolytically processed, two-
subunit structure. A variety of cell types have been shown to
differentially compartmentalize these two isoforms. For instance,
dendritic cells and macrophages retain TRAP 5b-like activity intra-
cellularly while secreting TRAP 5a-like activity to the medium [47–
49]. In osteoclasts, monomeric TRAP is secreted to the rufﬂed border,
where processing by cathepsin K yields the cleaved isoform detected
in the resorption lacuna [7]. In addition, the cleaved but not the
monomeric isoform is localized to vesicles of the endosomal–
lysosomal system as well as to the transcytotic pathway [7,50], and
eventually secreted into the circulation through the functional
secretory domain of the basolateral surface [50]. Since only a single
gene encoding TRAP has been identiﬁed in mammals [1,51,52], it has
been assumed that the TRAP isoforms are formed post-translationally
from a common monomeric precursor. With the purpose of assessing
the biogenetic relationships between these isoforms, the mammary
epithelial cancer cell line MDA-MB-231 with low basal expression of
the enzyme was chosen to establish a stable cell system over-
expressing 5a- and 5b-like TRAP isoforms.
In MDA-C11 cells, both monomeric and proteolytically processed
TRAP isoforms contributed to total TRAP activity. However, only TRAP
5a-like monomeric isoform, but not the 5b-like cleaved isoform was
Fig. 5. Effect of the cysteine proteinase inhibitors E64 and CA074-Me on proteolytic processing of TRAP expressed by MDA-C11 cells. (a) TRAP activity in cell lysates and
conditioned medium in MDA-C11 cells before and after treatment with E64. Data are presented as mean of three experiments±SD. (b, c) Elution pattern from FPLC Heparin
chromatography of (b) cellular TRAP and (c) secreted TRAP expressed by MDA-C11 cells following treatment with E64. Lysates containing equal amounts of protein (b) or equal
volumes of media (c) were loaded onto the column for each group. Horizontal bars under the peaks highlight the fractions pooled for further analysis of the peaks. (d)Western
blot analysis of eluted intracellular TRAP peaks of MDA-C11 before and after treatment with E64. (e) Elution pattern from FPLC Heparin chromatography of intracellular TRAP
expressed by MDA-C11 cells following treatment with CA074-Me. Lysates containing equal amounts of TRAP activity were loaded onto the column for each group.
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isoform and 5b-like cleaved isoform on Concanavalin A column
corroborates the previous ﬁndings of Kawaguchi et al.[53] that TRAP
5a and 5b exhibits differences in their sugar chain structures. Analysis
of N-linked oligosaccharide processing by endoglycosidase cleavage
and lectin chromatography also indicated that the majority of the
intracellular monomeric TRAP in MDA-C11 cells likely represented
the precursor of the secreted TRAP, while a minor proportion
provided the putative monomeric precursor for the intracellular 5b-
like isoform. Moreover, Brefeldin A blocked secretion of the 5a-likeisoform as well as appearance of its intracellular precursor, and
augmented the intracellular level of 5b-like isoform, indicating the
presence of a common early biosynthetic precursor for TRAP isoforms
5a and 5b. The cysteine proteinase inhibitor E64 partially blocked
formation of the 5b-like isoform, augmented the level of its putative
monomeric precursor, but did not alter the levels of secreted TRAP or
its intracellular precursor, suggesting that late monomeric precursors
for 5a- and 5b-like forms are segregated in the ER and Golgi prior to
proteolytic processing. Thus, these data provide evidence that distinct
monomeric TRAP populations are diverted early in the secretory
Table 2
Kinetic analysis of recombinant rat TRAP expressed by MDA-MB-231 cells.
KM n Fold activation at Vmax n pH optimum n
Peak M1 1.20 (0.32) 4 1 4 5.5 2
+CtsK 1.18 (0.31) 4 ×6.23 (0.93) 4 5.75 2
Peak L1a 0.94 (0.07) 4 1 4 5.5 2
+CtsK 0.94 (0.11) 4 ×4.70 (0.22) 4 5.75 2
Peak L2 0.64 (0.08) 4 1 4 ND ND
+CtsK 0.71 (0.12) 4 ×1.10 (0.09) 4 ND ND
Peak L3 0.54 (0.30) 4 1 4 5.75 2
+CtsK 0.66 (0.31) 4 ×1.12 (0.07) 4 5.75 2
Numbers in parentheses represent standard deviation values. ND, not determined.
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to intracellular, proteolytically processed TRAP isoform 5b.
TRAP is synthesized and secreted in large amounts by the
glandular epithelial cells of the porcine uterine endometrium during
pregnancy. Detailed characterization of TRAP secreted by these cells,
also known as uteroferrin, indicated that uteroferrin was a 35–37 kDa
monomeric protein [54] and newly synthesized uteroferrin from
endometrial explants contained complex- and high-mannose-type
oligosaccharides [55]. These ﬁndings are consistent with the data
presented in the current study where we showed epithelial MDA-C11
cells secrete only monomeric TRAP and secreted TRAP carries N-
linked high-mannose (EndoH-sensitive) and complex-type (EndoH-
resistant) oligosaccharides. Although this system provides a suitable
model to study intracellular trafﬁcking of TRAP in epithelial cells, its
potential relevance to macrophages and dendritic cells that have been
reported to secrete TRAP 5a in culture while retaining 5b-like activity
intracellularly [47] remains to be clariﬁed.
Macrophages and osteoclasts have been shown to contribute to
the presence of TRAP 5a and 5b isoforms in serum, respectively
[27,49]. TRAP 5b activity in serum correlates with osteoclast numbers
[23–25] and increased TRAP 5b activity in serum has been suggested
as a potential marker for osteolytic activity in metastatic bone disease
in breast, prostate and lung cancer patients [32,56–59]. Moreover, a
direct contribution to serum TRAP levels by TRAP expressed and
secreted bymalignant tumor cells was also proposed by a recent study
[15]. It remains to be determined whether tumor cells secrete
monomeric TRAP in vivo and whether TRAP 5a activity in serum
potentially contributed by tumor cells can be used as an additional
marker for the disease. In this study, we found that TRAP 5a-like
isoform secreted by mammary cancer cells exhibit a pH optimum
close to what is observed for the 5b isoform secreted by bone-
resorbing osteoclasts. This warrants caution in solely relying on pH
optimum measurements for determining relative contribution of
different TRAP isoforms to total TRAP activity in a sample in cases
where cellular sources of TRAP are not well characterized.
Cysteine proteinases such as cathepsin K, L and B, that are capable
of proteolytically processing and activating TRAP [6,7,14,60], have
been shown to be expressed by MDA-MB-231 cells [45,61]. Since
proteolytically processed forms of TRAP were abundant in MDA-C11
cells, we were therefore particularly interested in exploring the
possible involvement of cysteine proteinases in TRAP processing in
MDA-C11 cells by employing the cysteine proteinase inhibitors E64
and CA-074-Me. Quite similarly to its effect on mouse osteoclastic cell
line RAW264.7 [8], the general cysteine proteinase inhibitor E64
caused a decrease in the level of ﬁnal cleavage product L3 at the
expense of intermediate form L2 and their putative monomeric
precursor L1b. CA-074-Me is an alleged cathepsin B inhibitor which
has been shown to inactivate both cathepsin B and cathepsin L within
living cells [62], whereas the inhibitor does not inhibit cathepsin K in
osteoclasts [63]. Treatment of MDA-C11 cells with the inhibitor
showed that cathepsin B and L accounts for only a small portion of the
cysteine proteinase activity involved in proteolytic processing of TRAP
inMDA-MB-231 cells. Unfortunately, a direct assessment of the role ofcathepsin K in the process was hampered by the lack of availability of
speciﬁc and sufﬁciently selective intracellular inhibitors of the human
enzyme. However, our ﬁndings that kinetic properties of cleaved
isoforms of TRAP expressed by MDA-C11 cells were not altered upon
cathepsin K cleavage and MDA-MB-231 cells express cathepsin K
protein (data not shown) led us to speculate that cathepsin K could be
the main cysteine proteinase responsible for generation of ﬁnal
cleaved isoform L3.
Several lines of evidence support a role for TRAP in modulation of
cell adhesion and migration. A siRNA screening approach performed
as a systematic analysis of genes regulating epithelial cell migration
identiﬁed acp5, the gene encoding TRAP, as one of the genes whose
knockdown impaired the migration of epithelial cells [64]. We also
recently showed that TRAP, by virtue of its ability to dephosphorylate
osteopontin (OPN), regulates osteoclast adhesion and migration on
OPN [34]. In the light of these ﬁndings, the observed rounder
morphology of TRAP-overexpressing breast cancer cells might be
reﬂecting an altered adhesive, and possibly migratory capacity of the
cells. This intriguing phenotype warrants further studies to elucidate
the underlying molecular mechanisms.
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